cbdMD (YCBD) Return on Assets (2017 - 2026)

cbdMD (YCBD) posted Return on Assets of 0.0% for Q4 2025, down 4.87% sequentially from 0.0% in Q3 2025, and little changed YoY from 0.0% in Q4 2024.

cbdMD (YCBD) Return on Assets (2017 - 2026) Analysis & Trends

cbdMD has reported Return on Assets for 9 years, with the latest figure at 0.0% in Q4 2025.

Quarterly Return on Assets changed 0.0% year-over-year to 0.0% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
Return on Assets slipped to 0.0% in Q4 2025 per YCBD's latest filing, from 0.0% in the prior quarter.
Over five years, Return on Assets peaked at 0.0% in Q1 2021 and troughed at 0.01% in Q1 2023.
A 5-year average of 0.01% and a median of 0.0% in 2023 frame the typical range for Return on Assets.
The sharpest annual moves came in 2022 and 2024: Return on Assets decreased 1 bps in 2022, then rose 1 bps in 2024.
Over 5 years, Return on Assets stood at 0.0% in 2021, then plunged by 739 bps to 0.01% in 2022, then advanced by 11 bps to 0.01% in 2023, then soared by 81 bps to 0.0% in 2024, then advanced by 13 bps to 0.0% in 2025.
According to Business Quant data, Return on Assets over the past three periods registered 0.0%, 0.0%, and 0.0% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROA (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	0.00%
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	0.00%
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	0.00%
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	0.00%
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	0.00%
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	0.00%
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	0.00%
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	0.00%
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	0.00%
10	cbdMD	5.41 Mn	3.29 Mn	3.04 Mn	0.00%

Download Data